Group: Board of Directors

Embedded Sources:

Use Case: Women's Health

Empowering Women with
Real-Time Hormonal Insight.

Millions of women struggle with hormone-related health issues, from irregular cycles and fertility challenges to menopause and hormone-sensitive conditions. Yet hormone levels are dynamic, and current tests offer only static snapshots, often missing key changes or trends.

KIFFIK’s ISF platform could continuously or intermittently monitor hormones like estrogen, progesterone, and LH in a non-invasive, user-friendly way. This opens the door to proactive management of fertility, cycle regulation, and personalized hormonal therapies — all without frequent lab visits.

Real-time ovulation tracking and cycle phase identification
Monitoring hormone replacement therapy in menopause
Early detection of hormonal imbalances (e.g., PCOS, amenorrhea)

Estradiol (E2)
Luteinizing Hormone (LH)
Progesterone
Follicle-Stimulating Hormone (FSH)
Anti-Müllerian Hormone (AMH)

Use Case: Military & PolyTrauma

Field-ready diagnostics for
high-consequence decisions.

In military and trauma settings, rapid diagnosis can mean the difference between life and loss. Yet current tools often require centralized labs, invasive procedures, or lag-time results — none of which are ideal in field, combat, or mass casualty environments.

KIFFIK’s non-invasive ISF platform could deliver real-time biomarker data directly at the point of injury — enabling rapid triage, injury stratification, and early detection of complications like internal bleeding, systemic inflammation, or infection. Designed for portability and ease of use, the platform can support frontline teams with fast, actionable insight.

Triage of blast injuries, blunt trauma, and polytrauma
Early detection of inflammatory cascade and internal bleeding
Remote deployment in field hospitals, medevac, or battlefield medicine

Interleukin-6 (IL-6)
S100B (neurotrauma indicator)
Lactate (tissue hypoxia)
D-dimer (coagulation dysfunction)
Myoglobin (muscle damage)
TNF-α (systemic inflammation)

Use Case: Prostate Cancer

Precision Monitoring for a
Leading Men’s Health Challenge

Prostate cancer is the second most common cancer in men globally. Yet current monitoring tools, like PSA blood tests or invasive biopsies, often lack specificity, are performed infrequently, and can lead to overtreatment or missed progression. Clinicians need better tools to distinguish between indolent and aggressive disease in real time.

KIFFIK’s non-invasive ISF platform offers continuous or on-demand biomarker monitoring that could detect early biochemical changes associated with disease onset, progression, or treatment response. By bypassing the need for repeated blood draws or delayed lab tests, the platform supports personalized surveillance strategies and more confident clinical decisions.

Early detection and screening for high-risk populations
Monitoring treatment efficacy and therapeutic resistance
Active surveillance of low-risk prostate cancer without invasive biopsies

Prostate-Specific Antigen (PSA)
PCA3 (Prostate Cancer Antigen 3)
Alpha-methylacyl-CoA racemase (AMACR)
Circulating tumor DNA (ctDNA) for mutation profiling
Interleukin-8 (IL-8) and other inflammation markers

ISF Research & Biomarker Discovery

Accelerating discovery
from tissue to therapy.

Biomarker discovery is central to advancing precision medicine, but most research depends on invasive blood sampling or static lab tests. These limitations reduce sampling frequency, overlook localized biological signals, and make real-world longitudinal data difficult to obtain. Critical biomarkers can remain undetected, or misunderstood, without a more accessible and dynamic sampling medium.

KIFFIK Lab offers scalable, repeatable access to interstitial fluid (ISF), providing researchers with a unique window into tissue-adjacent biology. By enabling real-time collection of molecular data, without blood draws, KIFFIK transforms how biomarkers are discovered, validated, and monitored. Our platform supports translational research across therapeutic areas with minimal burden on participants.

Early-phase biomarker discovery in immune, metabolic, and oncologic pathways
Pharmacodynamic and pharmacokinetic profiling in clinical trials
Companion diagnostic development in personalized medicine
Population-scale studies using decentralized, non-invasive sampling

IL-6, CRP (inflammatory signaling)
Adiponectin, leptin (metabolic regulation)
VEGF, IL-8 (oncogenic pathways)
S100B, GFAP (neuroinflammatory injury)

Use Case: Sepsis

Catching the cascade
before it crashes the system.

Sepsis progresses rapidly and often invisibly in its early stages. Current diagnostic tools rely on lagging indicators or generalized clinical signs, leaving critical intervention windows missed.

KIFFIK’s platform offers the potential to detect sepsis-associated biomarkers in ISF at the earliest stages of dysregulation. This enables real-time insight into immune response and systemic inflammation — allowing for faster, more targeted intervention when it’s most needed.

Emergency departments
ICUs and high-risk inpatient settings
Resource-limited environments and field hospitals

Procalcitonin (PCT)
C-reactive protein (CRP)
Interleukin-6 (IL-6)
TNF-α (Tumor Necrosis Factor-alpha)
Lactate

Use Case: Skin Health

Turning the surface into
a source of insight.

Skin is the body’s largest organ — and one of the most visible — yet its health is often assessed only through surface observation or delayed biopsies. Whether in dermatology clinics or personal care, there’s limited access to underlying biological signals that reveal what’s really happening beneath the surface.

By accessing biomarkers directly from interstitial fluid within the skin, KIFFIK’s platform may unlock real-time, molecular-level insight into inflammation, immune activity, and cellular stress. This supports both clinical care and proactive skin wellness — from chronic disease management to personalized skincare.

Dermatology: Non-invasive assessment of skin inflammation, disease flares (e.g., eczema, psoriasis), and potentially early indicators of melanoma or other skin cancers
Beauty & Wellness: Real-time monitoring of skin barrier integrity, hydration, oxidative stress, and treatment response for personalized skincare routines

Interleukin-1α (IL-1α)
Interleukin-8 (IL-8)
TNF-α
MMP-9 (Matrix metalloproteinase-9)
Reactive oxygen species (ROS)
Natural moisturizing factor (NMF) markers

Use Case: Traumatic Brain Injury (TBI)

Real-time insight into
invisible injuries

TBI often presents without visible symptoms, especially in early stages. Traditional tools like imaging and clinical exams can miss subtle, evolving changes — delaying care when time is critical.

Through interstitial fluid, KIFFIK’s platform may enable early detection of TBI by capturing biomarker signals linked to inflammation, neurotrauma, and cellular stress. This could transform how we identify and manage brain injury — from emergency departments to military and athletic settings.

Emergency medicine
Sports concussion protocols
Military and remote triage

GFAP (Glial Fibrillary Acidic Protein)
UCH-L1 (Ubiquitin C-terminal hydrolase L1)
S100B
Interleukin-6 (IL-6)
Tau protein fragments

Use Case: Colorectal Cancer

Early detection without delay
— or discomfort.

Colorectal cancer is the second leading cause of cancer-related deaths, yet screening rates remain low due to fear, discomfort, and the invasiveness of traditional tests. Many cases go undetected until advanced stages, when outcomes are poorer and costs are higher.

KIFFIK Lab delivers a non-invasive, point-of-care test for colorectal cancer screening — offering a patient-friendly alternative to colonoscopy, blood draws, and stool-based tests. By accessing ISF biomarkers through the skin, our platform enables earlier insight, faster decision-making, and broader screening access.

Routine screening in primary care and outpatient settings
Non-invasive option for screening-hesitant populations
Expanded access for underserved and remote communities

Carcinoembryonic antigen (CEA)
Methylated DNA markers (e.g., SEPT9)
MMP-9 (Matrix metalloproteinase-9)
Interleukin-8 (IL-8)
Calprotectin (inflammatory marker)

Group: Board of Directors

Mike Tudeen

Steve Reindl​

Blake Carver​

Mike Gallup​

Hap Peterson​

Brian T. Dougan, Esquire

George Cagna​

Navigation

FOLLOW US

Estradiol (E2)

Luteinizing Hormone (LH)

Progesterone

Follicle-Stimulating Hormone (FSH)

Anti-Müllerian Hormone (AMH)

Interleukin-6 (IL-6)

S100B (neurotrauma indicator)

Lactate (tissue hypoxia)

D-dimer (coagulation dysfunction)

Myoglobin (muscle damage)

TNF-α (systemic inflammation)

Prostate-Specific Antigen (PSA)

PCA3 (Prostate Cancer Antigen 3)

Alpha-methylacyl-CoA racemase (AMACR)

Circulating tumor DNA (ctDNA) for mutation profiling

Interleukin-8 (IL-8) and other inflammation markers

IL-6, CRP (inflammatory signaling)

Adiponectin, leptin (metabolic regulation)

VEGF, IL-8 (oncogenic pathways)

S100B, GFAP (neuroinflammatory injury)

Procalcitonin (PCT)

C-reactive protein (CRP)

Interleukin-6 (IL-6)

TNF-α (Tumor Necrosis Factor-alpha)

Lactate

Interleukin-1α (IL-1α)

Interleukin-8 (IL-8)

TNF-α

MMP-9 (Matrix metalloproteinase-9)

Reactive oxygen species (ROS)

Natural moisturizing factor (NMF) markers

GFAP (Glial Fibrillary Acidic Protein)

UCH-L1 (Ubiquitin C-terminal hydrolase L1)

S100B

Interleukin-6 (IL-6)

Tau protein fragments

Carcinoembryonic antigen (CEA)

Methylated DNA markers (e.g., SEPT9)

MMP-9 (Matrix metalloproteinase-9)

Interleukin-8 (IL-8)

Calprotectin (inflammatory marker)

Steve Reindl

Blake Carver

Mike Gallup

Hap Peterson

George Cagna